New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 14, 2014
16:06 EDTINTCIntel used $4.2B to repurchase 122M shares of stock in Q3
Subscribe for More Information
16:06 EDTINTCIntel CEO says 'pleased by the progress the company is making'
Subscribe for More Information
16:05 EDTINTCIntel sees FY14 CapEx $11B, plus or minus $500M
16:04 EDTINTCIntel reports Q3 PC Client Group revenue $9.2B, up 6% sequentially, up 9% YoY
Subscribe for More Information
16:02 EDTINTCIntel reports Q3 gross margin 65%
Subscribe for More Information
16:02 EDTINTCIntel sees Q4 revenue $14.7B, plus or minus $500M, consensus $14.49B
Subscribe for More Information
16:01 EDTINTCIntel reports Q3 EPS 66c, consensus 65c
Subscribe for More Information
15:29 EDTINTCNotable companies reporting after market close
Subscribe for More Information
14:45 EDTINTCEarnings Preview: Intel to report after Microchip correction warning
Subscribe for More Information
14:03 EDTMDTMedtronic announces FDA approval of pacing lead for full-body MRI scans
Subscribe for More Information
13:59 EDTVRTXVertex mentioned cautiously at BofA/Merrill
12:41 EDTJNJGilead retreats following Johnson & Johnson comments on HCV drug
Shares of Gilead (GILD), which has developed a hepatitis C treatment, are retreating after Johnson & Johnson (JNJ) said it would seek to make its own hepatitis C treatment accessible and competitive. Some investors believe that Johnson & Johnson's comments suggest that it will cut the price of its hepatitis C drug. WHAT'S NEW: Johnson & Johnson said on its earnings conference call today that it was "committed" to its treatment for hepatitis C virus, or HCV. The company added that it intends to remain competitive in the space and would look to make its HCV treatment, Olysio, accessible. In a separate development today, The Wall Street Journal reported that Abbvie (ABBV), which also has an HCV treatment, may have to consider pricing its HCV drug more aggressively after Gilead received FDA approval for Harvoni, the first combination pill approved to treat chronic HCV genotype 1 infection. One analyst quoted by The Journal, Roger Longman, said that AbbVie should consider pricing its drug at $76,000 for a 12 week regimen, representing a 20% discount to Harvoni, which will be priced at $94,500 for a full 12 week regimen. ANALYST REACTION: In a note to investors earlier today, RBC Capital analyst Michael Yee wrote that the weakness in Gilead's stock today has created a buying opportunity. Johnson & Johnson probably can't reduce the price of its Olysio drug much, since it is often used in combination with Gilead's Sovaldi, which costs $84,000 for 12 weeks, RBC Capital analyst Michael Yee wrote in a note to investors today. The price of AbbVie's treatment is unlikely to be much below Sovaldi's price, the analyst stated. WHAT'S NOTABLE: Gilead, along with a number of other drug companies, may also be under pressure because Ireland is reportedly closing its "Irish Double" tax loophole. Gilead is one of the companies that currently benefits from the "Irish Double," but Yee says that closing the loophole should only have a "minimal" impact on Gilead. PRICE ACTION: In early afternoon trading, Gilead fell 3.3% to $98.10, AbbVie gained 1.7% to $54.53 and Johnson & Johnson lost 0.6% to $98.52.
12:33 EDTJNJZimmer, Stryker have postive read-through from J&J, says Wells Fargo
Subscribe for More Information
12:31 EDTINTCIntel October 32.5 straddle priced for 6% move into Q3
Subscribe for More Information
12:20 EDTJNJOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday after three of the nation's largest banks reported on their results in the most recent quarter of the year. The market began the session in positive territory but the move seemed tenuous and the averages were almost back in negative ground within a half hour of the opening bell. As the morning progressed and the bears were unable to gain control, the buyers emerged and pushed the Dow to a triple digit gain and the Nasdaq to an increase of nearly 1.5%. ECONOMIC EVENTS: In the U.S., the National Federation of Independent Business' small business optimism index came in at 95.3, versus the consensus expectation for a 95.8 reading. COMPANY NEWS: JPMorgan (JPM) swung to a third quarter profit, but its headline earnings per share fell below analystsí consensus estimate. Of note, the company's press release on its results came out earlier than planned on Nasdaq's (NDAQ) Shareholder.com website, which the exchange operator attributed to an internal "human error." Wells Fargo (WFC) reported in-line earnings and stronger credit quality, but its stock slid 1.4% following the report. Citigroup (C) generated the most headlines, however, as it reported better than expected adjusted third quarter profit, announced plans to pull back from retail banking in eleven countries and said it will disband a legacy Banamex unit that provided personal security services after an investigation uncovered illegal conduct. Shares of Citi bucked the trend set by its two peers, rising 3% near noon... In addition to JPMorgan, Dow member Johnson & Johnson (JNJ) reported on its third quarter earnings. The drug and medical device giant reported better than expected profits and revenues and raised its FY14 EPS outlook, but the stock was fractionally lower near midday. MAJOR MOVERS: Among the notable gainers was Energy Transfer Equity (ETE), which gained 8.5% after the stock was among the energy industry names upgraded this morning at RW Baird. Also higher was Skyworks (SWKS), which rose 11% after the company preannounced stronger than expected results that its CEO attributed to the "broad-based strength" of its business. Among the noteworthy losers was EnerNOC (ENOC), which dropped 11% after JPMorgan downgraded the stock to Neutral citing risk to the company's Demand Response revenue at PJM given the challenge to FERC Rule 745. Also lower was Tyco (TYC), which fell nearly 4% after Barclays downgraded the stock citing valuation and coupled the ratings change with an upgrade of Eaton (ETN). INDEXES: Near midday, the Dow was up 133.38, or 0.82%, to 16,454.45, the Nasdaq was up 60.63, or 1.44%, to 4,274.29, and the S&P 500 was up 21.51, or 1.15%, to 1,896.25.
11:39 EDTINTCIntel technical comments ahead of earnings
The shares have outperformed the broader averages over the last three months. Removing today's bounce, the stock has been flat against the down performance of the averages. The trading pattern for the stock when viewed with a three-month window has been up sharply, sideways, and down sharply. That doesn't leave a great deal of room for trend interpretation other than traders being cautious into results. When we pull back to a 1-year view, the technical picture is strikingly different. Almost all of the gains in shares this year, up over 34% excluding today, has come since the early summer. That sharp rise then developed into a bearish rounding formation viewed on a closing basis. On an OHLC chart, the formation instead is an Island Top. That is, a bullish gap, the sideways move previously described, and a bearish gap from yesterday. That leaves the price action of the last several months isolated, an island, within the context of the longer term uptrend. Island Tops are usually considered extremely bearish on a technical basis, suggesting the up move has exhausted itself in a blow-off. If the news on earnings and outlook supports this bearish price interpretation, there could be significant downside risk. Levels to watch on the downside would be at $31.80, the bottom of the bullish gap from July, $30,03, and $28.10, the bottom of the bullish gap from June. A break below $28 might leave the shares back in the $24 to $26 range characteristic of the price action at the start of the year. If the news is positive, the first major resistance is at the 52-week high at $35.56 and then at $37.15.
11:23 EDTJNJBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:11 EDTJNJJohnson & Johnson Ortho strength positive for Zimmer, says Piper Jaffray
Piper Jaffray said Johnson & Johnson's (JNJ) sequential Q3 strength in orthopedics, which included acceleration in both hips and knees, was surprising and a positive for Zimmer (ZMH). However, Piper expect sentiments on ortho names to remain muted until further into reporting season, noting that Stryker (SYK) is scheduled to report Thursday after the close. The firm has Neutral rating on Johnson & Johnson and Stryker and an Overweight rating on Zimmer.
10:51 EDTJNJGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:41 EDTJNJGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use